STAT+: GSK touts lung cancer data from two drugs

Phase 3MixedDefinium LSD treatmentAstraZeneca breast cancer drugNeutral

AI Analysis

Summary

GSK reported positive late-stage lung cancer data for Definium's LSD treatment while AstraZeneca's breast cancer drug failed a key trial. Mixed clinical results across multiple oncology programs.

Outcome Details

GSK touts lung cancer data from Definium drug; AstraZeneca breast cancer drug fails key trial

Importance:5/10

Sentiment:

0.00

lung cancerbreast cancerlate-stage resultstrial failure

Related Companies

$GSK $AZN

Read the original article

Published by STAT News on September 14, 2026 1:34 PM

Read Original